Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4913MR)

This product GTTS-WQ4913MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 608
UniProt ID Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4913MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4561MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ11741MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ1606MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ9610MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ8014MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GZ-402668
GTTS-WQ4418MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-663513
GTTS-WQ7263MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ6236MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CR57
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW